- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Reports: ESI may start 'price war' over new hepatitis C drugs
PHILADELPHIA — Lannett has received regulatory approval from the Food and Drug Administration for its version of an antipsychotic treatment.
The drug maker said the FDA approved its abbreviated new drug application for loxapine capsules in the 5-mg, 10-mg, 25-mg and 50-mg strengths. The drug is a generic version of Watson Pharmaceuticals' Loxitane.
“We have now received five product approvals from the FDA over the last three months,” Lannett president and CEO Arthur Bedrosian said. “Loxapine capsules is an important addition to our product lineup.”